| アブストラクト | BACKGROUND: Phosphodiesterase 5 inhibitors (PDE5i) are the standard medical treatment for erectile dysfunction. Aim of our study was to evaluate the rate of major adverse cardiovascular events (MACE) reported during PDE5i treatment based on Eudra-Vigilance (EV) reports. METHODS: EV database is the system for managing and analyzing data on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area. MACE are defined as non-fatal stroke, non-fatal myocardial infarction, non-fatal congestive heart failure, revascularization after aorto-coronary graft bypass and cardiovascular death. We recorded the number of MACE for sildenafil, tadalafil, vardenafil, avanafil per category and severity until 1(st) July 2023. Pooled Relative Risk (PRR) was used to compare data between drugs. RESULTS: Overall, 951 MACE events were reported. Most of them were observed in younger patients <65 years old (452/951 events, 48%). Overall, 377/8939 (4%) MACE events were observed for sildenafil, 221/5213 (4%) for tadalafil, 50/1029 (4%) for vardenafil and no events for avanafil. No significative differences were reported comparing sildenafil and tadalafil (PRR 0.71-0.99, IQR 0.61-1.35, P>0.05), neither sildenafil vs. vardenafil (PRR 0.68-0.79, IQR 0.43-1.55, P>0.05), neither tadalafil vs. vardenafil (PRR 0.77-0.95, IQR 0.64-1.30. P>0.05) even when compared for age. Comparison between different classes of age showed MACE were more frequent in patients younger than 65 years old taking sildenafil and tadalafil when compared to patients older than 85 years old (PRR 0.02-0.11. IQR 0.01-0.40. P<0.01) and when compared to patients in 65-85 class of age (PRR 0.02-0.12, IQR 0.01-0.95, P<0.01). CONCLUSIONS: Real life data is consistent with MACE related to PDE5i. PDE5is are infrequently (<5%) associated with MACE. However, risk seems higher in younger patients, particularly for sildenafil (452/951 events, 48%). Clinicians should consider these data when prescribing PDE5i especially in young patients. |
|---|
| ジャーナル名 | Minerva urology and nephrology |
|---|
| Pubmed追加日 | 2024/3/19 |
|---|
| 投稿者 | DE Nunzio, Cosimo; Nacchia, Antonio; Grimaldi, Maria C; Turchi, Beatrice; Rovesti, Lorenzo; Franco, Antonio; Guarnotta, Giorgio; Voglino, Olivia; Mancini, Elisa; Baldassarri, Valeria; Lombardo, Riccardo; Cicione, Antonio; Tubaro, Andrea |
|---|
| 組織名 | Sant'Andrea Hospital, Sapienza University, Rome, Italy -;cosimodenunzio@virgilio.it.;Sant'Andrea Hospital, Sapienza University, Rome, Italy.;Department of Cardiovascular and Pneumological Sciences, Sacred Heart Catholic;University, Rome, Italy.;Department of Cardiovascular Sciences, IRCCS A. Gemelli University Polyclinic;Foundation, Rome, Italy. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38498298/ |
|---|
